Immune checkpoint inhibitors of programmed cell death 1 protein moved rapidly into clinical practice following US Food and Drug Administration approval, but patients treated in clinical practice were older than those who participated in the pivotal clinical trials. READ MORE

News

Immune checkpoint inhibitors of programmed cell death 1 protein moved rapidly into clinical practice following US Food and Drug Administration approval, but patients treated in clinical practice were older than those who participated in the pivotal clinical trials.

READ MORE

A recent study assessed whether combining a targeted therapy with an immunotherapy for ALK translocation-positive advanced non-small cell lung cancer results in more durable patient responses.

READ MORE

A recent survey highlighted the need for educational resources to go further in-depth into immunotherapy science and management strategies for treatment-related adverse events.

READ MORE

Targeted next-generation sequencing may accurately estimate tumor mutation burden in NSCLC, which may further shed light on the likelihood of benefit from immune checkpoint inhibitors in individual patients.

READ MORE

Resources

The American Society of Clinical Oncology and the National Comprehensive Cancer Network have collaborated for the first time to release new clinical guidelines for managing immunotherapy-related toxicities.

READ MORE

The International Association for the Study of Lung Cancer has launched a guideline for nurses and clinicians who are treating lung cancer with immunotherapy and encounter adverse events.

READ MORE

Conferences

From January 25-27, the American Society of Clinical Oncology hosted its Clinical Immuno-Oncology Symposium in San Francisco, California. The meeting will highlight some of the largest updates in clinical and translational research in immuno-oncology and the implications for clinical care.

READ MORE